CD34 and neoplasm: The strategies include the design of dual targeting mCART to enhance tumor antigen recognition, the utilization of cytokine co-expression to improve the survival and infiltrating capacities of mCART, the development of combination therapy with checkpoint inhibitors to boost mCART performance by counteracting immunoevasion, and the construction of hu-CD34-NSGTM and PDX mice models to mimic human TME for mCART mechanism research [60–65].